Early Intervention in High-Risk Smoldering Myeloma: Results From the AQUILA Study at ASH 2024

December 20, 2024

Saad Z. Usmani, MD, MBA, FACP

Opinion

Video

Saad Z. Usmani, MD, MBA, FACP, discusses how the AQUILA study data presented at ASH 2024, highlighting the benefits of early intervention in high-risk smoldering multiple myeloma, could impact treatment strategies by improving progression-free survival, while also addressing potential drawbacks of intervening too early in the disease course.

Now Viewing

EP: 1.Early Intervention in High-Risk Smoldering Myeloma: Results From the AQUILA Study at ASH 2024

EP: 2.Exploring the Frontline Potential of Teclistamab: Insights From MajesTEC-5 at ASH 2024

EP: 3.MRD Outcomes From CEPHEUS at ASH 2024

EP: 4.Transplant-Ineligible Myeloma and MRD Integration: Current Definitions and Future Directions

Video content above is prompted by the following:

Coming into ASH 2024, what would did consider to be the largest unmet need in the treatment and management of multiple myeloma?
Discuss the data presented at the 2024 ASH Annual Meeting from the AQUILA study in high-risk smoldering multiple myeloma. (Abstract)
What was the objective of this study?
How was this study designed/what methodology was used?
What results were presented?
Primary end point: progression-free survival, median not reached for daratumumab vs 41.5 for active observation
What are your key takeaways from this study, and how might this data impact the way high-risk smoldering multiple myeloma is managed?
What potential drawbacks could arise from intervening this early in the disease course of multiple myeloma?

Related Content

ICYMI: Highlights From AMCP Nexus 2024

December 26th 2024

Article

Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.

ICYMI: Highlights From ASCO 2024

December 21st 2024

Article

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

ICYMI: Highlights From SLEEP 2024

December 18th 2024

Article

Check out our top 5 most-viewed pieces of coverage from the 2024 SLEEP meeting.

ICYMI: Highlights From ACTRIMS 2024

December 12th 2024

Article

Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS).